Scala Biodesign develops cutting-edge computational protein design solutions to address complex protein development challenges in the pharmaceutical, chemical, diagnostics and food sectors. Antibodies, vaccines and sustainable chemical manufacturing demand proteins that meet exceptionally stringent requirements in activity, shelf-life and safety. Yet, traditional methods for protein engineering are costly, lengthy and failure-prone. Scala’s one-shot approach dramatically accelerates the development process, increases success rates and slashes R&D efforts, thereby enabling its partners to pursue challenging projects that were previously beyond their reach. Scala has partnered with some of the largest pharma and chemical corporations worldwide and its technology has successfully overcome development challenges that confounded expert teams for years.
Scala, under the leadership of Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), leverages the technologies they developed in the group of Prof. Sarel Fleishman (Chief Scientist) which was licensed from the Weizmann Institute of Science. Scala is positioned to become the primary destination for corporations venturing into new protein-based product development.
